| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Jennifer Scott Perry | COO | 2026-10-05 | 326 | $3.78 | $1.23kSell |
| Jennifer Scott Perry | COO | 2026-10-05 | 80 | $3.56 | $284.80Sell |
| Jennifer Scott Perry | COO | 2026-10-05 | 326 | $3.78 | $1.23kSell |
| Jennifer Scott Perry | COO | 2026-10-05 | 80 | $3.56 | $284.80Sell |
| Michael Charles Ferguson Hannay | CXO | 2026-10-05 | 242 | $3.57 | $863.94Sell |
| Michael Skynner | CSci | 2026-10-05 | 503 | $3.57 | $1.80kSell |
| Jennifer Scott Perry | COO | 2026-10-05 | 326 | $3.78 | $1.23kSell |
| Travis Alvin Thompson | CFO | 2026-10-05 | 79 | $3.57 | $282.03Sell |
| Kevin Lee | CEO | 2026-10-05 | 1,638 | $3.57 | $5.85kSell |
| Jennifer Scott Perry | COO | 2026-10-05 | 30 | $3.57 | $107.10Sell |
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Baker Bros Advisors LP | 14.29% | 10,018,674 | $33.76M | Insider |
| Carolyn Ng | 2.85% | 1,998,580 | $6.74M | Insider |
| Tybourne Capital Management Hk Ltd | 2.79% | 1,957,961 | $6.60M | Insider |
| Deborah Harland | 2.73% | 1,915,275 | $6.45M | Insider |
| Svlsf V LLC | 2.73% | 1,915,274 | $6.45M | Insider |
| Glaxosmithkline PLC | 2.73% | 1,910,531 | $6.44M | Insider |
| Kate Bingham | 2.72% | 1,910,016 | $6.44M | Insider |
| Novartis Bioventures Ltd | 2.52% | 1,769,641 | $5.96M | Insider |
| Michael Anstey | 2.50% | 1,751,437 | $5.90M | Insider |
| Cambridge Innovation Capital Jersey Ltd | 2.50% | 1,751,437 | $5.90M | Insider |